Investigation of the interplay of PCSK9, cardiac dynamics, oxidative stress in coronary artery disease: case-control study
Frontiers in Endocrinology · 2025
DOI: 10.3389/fendo.2025.1494438 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Frontiers in Endocrinology, 2025. Verfasst von Anmar Hussein Lafta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Oxidative Stress, Proprotein Convertase 9, Coronary Artery Disease. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
PCSK9 plays a key role in raising LDL-C levels, which contributes to heart attacks (MI). However, studies show that about half of MI patients have normal LDL-C levels. This study aims to explore the link between PCSK9, heart function, and oxidative stress markers in MI patients.
Methods
This investigation was carried out at Tehran Heart Centre Hospital on healthy individuals (n=63) and patients (n=63) with MI who had a coronary artery block above 50% (CAB > 50%). Oxidative stress (OS) parameters, such as total antioxidant capacity (TAC), malondialdehyde (MDA), myeloperoxidase (MPO), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activity, PCSK9, oxidized Low-density lipoprotein (ox-LDL), high-sensitivity cardiac troponin I (hs-cTnI), and hs-CRP are assessed. Indeed, biochemical parameters and EF% were measured.
Results
Higher EF% (>37.5%), TAC (>1.05 mmol Fe² + ;/L), GPx (>16.48 mU/mL), CAT (>11.32 nmol/min/mL), and SOD (>297.16 U/mL) were linked to a lower risk of CAB > 50%. In contrast, higher MDA (>32.07 nmol/mL), MPO (>17.77 U/L), hs-CRP (>5.5 mg/L), and ox-LDL (>64.87 μg/L) were associated with a higher risk. There was no significant difference in PCSK9 and LDL-C levels between groups. EF% was positively linked to SOD but negatively related to MDA, MPO, ox-LDL, hs-cTnI, and hs-CRP. Ox-LDL correlated positively with MPO but negatively with TAC, CAT, and GPx. PCSK9 showed a positive relationship with MDA. The best markers for CAB > 50% diagnosis were ox-LDL (AUC = 83.22, cut-off > 63.35 μg/L), EF% (AUC = 82.35, cut-off < 46.25%), and hs-cTnI (AUC = 81.3, cut-off > 0.265 ng/mL).
Conclusion
While PCSK9’s role in MI through LDL-C is well known, its impact on inflammation and oxidative stress may also be important, even when LDL-C and PCSK9 levels are normal. Additionally, ox-LDL and EF% are better indicators of CAB > 50% than hs-cTnI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences, Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Lafta, A. H., Shiri, H., Iraji, M., Karimpour, A., Sattari, M., Rahimkhani, M., Einollahi, N., & Panahi, G. (2025). Investigation of the interplay of PCSK9, cardiac dynamics, oxidative stress in coronary artery disease: case-control study. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1494438
Vancouver
Lafta AH, Shiri H, Iraji M, Karimpour A, Sattari M, Rahimkhani M, et al. Investigation of the interplay of PCSK9, cardiac dynamics, oxidative stress in coronary artery disease: case-control study. Frontiers in Endocrinology. 2025. doi:10.3389/fendo.2025.1494438
BibTeX
@article{Lafta2025,
author = {Lafta, Anmar Hussein and Shiri, Hamidreza and Iraji, Mahsa and Karimpour, Amin and Sattari, Mahboobe and Rahimkhani, Monireh and Einollahi, Nahid and Panahi, Ghodratollah},
title = {Investigation of the interplay of PCSK9, cardiac dynamics, oxidative stress in coronary artery disease: case-control study},
journal = {Frontiers in Endocrinology},
year = {2025},
doi = {10.3389/fendo.2025.1494438}
}
EUVIMED